Enhancement of photodynamic therapy by 2,5-dimethyl celecoxib, a non-cyclooxygenase-2 inhibitor analog of celecoxib.

@article{Ferrario2011EnhancementOP,
  title={Enhancement of photodynamic therapy by 2,5-dimethyl celecoxib, a non-cyclooxygenase-2 inhibitor analog of celecoxib.},
  author={Angela Ferrario and Sophia Lim and F. Xu and Marian C. Luna and Kevin J. Gaffney and Nicos A Petasis and Axel H Sch{\"o}nthal and Charles J. Gomer},
  journal={Cancer letters},
  year={2011},
  volume={304 1},
  pages={33-40}
}
Photodynamic therapy (PDT) effectiveness can be improved by employing combined modality approaches involving pharmaceuticals targeting the tumor microenvironment and/or tumor cell death pathways. In one approach, combining PDT with celecoxib improves long-term tumoricidal activity without increasing normal tissue photosensitization. However, side effects arising from the use of coxib based cyclooxygenase-2 (COX-2) inhibitors, including cardiovascular injury, decreases the clinical applications… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
Enhancement of photodynamic therapy by 2,5-dimethyl celecoxib , a non - cyclooxygenase-2 inhibitor analog of celecoxib .
A growing number of studies demonstrate that the tumoricidal actions of coxibs such as celecoxib involve non - COX-2 mediated mechanisms .
The celecoxib analog , 2,5-dimethyl celecoxib ( DMC ) , lacks COX-2 inhibitory activity but exhibits cytotoxic properties comparable to the COX-2 inhibitor celecoxib .
The celecoxib analog , 2,5-dimethyl celecoxib ( DMC ) , lacks COX-2 inhibitory activity but exhibits cytotoxic properties comparable to the COX-2 inhibitor celecoxib .
The celecoxib analog , 2,5-dimethyl celecoxib ( DMC ) , lacks COX-2 inhibitory activity but exhibits cytotoxic properties comparable to the COX-2 inhibitor celecoxib .
Enhancement of photodynamic therapy by 2,5-dimethyl celecoxib , a non - cyclooxygenase-2 inhibitor analog of celecoxib .
Neoplastic CellIs abnormal cell of diseaseNeoplasms
Photodynamic therapy ( PDT ) effectiveness can be improved by employing combined modality approaches involving pharmaceuticals targeting the tumor microenvironment and/or tumor cell death pathways .
A growing number of studies demonstrate that the tumoricidal actions of coxibs such as celecoxib involve non - COX-2 mediated mechanisms .
Enhancement of photodynamic therapy by 2,5-dimethyl celecoxib , a non - cyclooxygenase-2 inhibitor analog of celecoxib .
Enhancement of photodynamic therapy by 2,5-dimethyl celecoxib , a non - cyclooxygenase-2 inhibitor analog of celecoxib .
The celecoxib analog , 2,5-dimethyl celecoxib ( DMC ) , lacks COX-2 inhibitory activity but exhibits cytotoxic properties comparable to the COX-2 inhibitor celecoxib .
The celecoxib analog , 2,5-dimethyl celecoxib ( DMC ) , lacks COX-2 inhibitory activity but exhibits cytotoxic properties comparable to the COX-2 inhibitor celecoxib .
The celecoxib analog , 2,5-dimethyl celecoxib ( DMC ) , lacks COX-2 inhibitory activity but exhibits cytotoxic properties comparable to the COX-2 inhibitor celecoxib .
All Topics